Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2019-10-07 19:23:07
Reporting Period:
Accepted Time:
2019-10-07 19:23:07
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1781983 Aprea Therapeutics Inc. APRE () 4
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1187572 Iii B John Henneman 535 Boylston Street
Boston MA 02116
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-10-07 5,000 $15.00 5,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to Buy) Acquisiton 2019-10-07 18,407 $0.00 18,407 $15.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
18,407 2029-10-02 No 4 A Direct
  1. Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.